Liminatus Pharma, Inc. (LIMNW)La Palma, United States | NasdaqCM
0.06 USD
Short-term: ☆☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 10:10 p.m. EDT
Critical distress signal: Limited cash (approx $337k) versus significant debt ($1.44M) creates immediate liquidity risk, compounded by explicit risk of dilution and delisting. The stock is flat at its 52-week low with zero momentum, making a 'buy' or 'hold' stance untenable. |
| Attribute | Value |
|---|---|
| Beta | 0.63 |
| Previous Name | Liminatus Pharma, LLC |
| Website | https://liminatuspharma.com |
| Attribute | Value |
|---|---|
| Address1 | 6 Centerpointe Drive |
| Address2 | #625 |
| Ask | 0.1706 |
| Ask Size | 1 |
| Beta | 0.628 |
| Bid | 0.31 |
| Bid Size | 10 |
| Book Value | -0.363 |
| City | La Palma |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.0579 |
| Current Ratio | 0.049 |
| Custom Price Alert Confidence | HIGH |
| Day High | 0.0579 |
| Day Low | 0.0579 |
| Display Name | Liminatus Pharma |
| Ebitda | -2,965,984 |
| Ebitda Margins | 0.0 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Two Week High | 0.0579 |
| Fifty Two Week High Change | 0.0 |
| Fifty Two Week High Change Percent | 0.0 |
| Fifty Two Week Low | 0.0579 |
| Fifty Two Week Low Change | 0.0 |
| Fifty Two Week Low Change Percent | 0.0 |
| Fifty Two Week Range | 0.0579 - 0.0579 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,772,807,400,000 |
| Float Shares | 29,071,731 |
| Free Cashflow | 7,141,122 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 1 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Industry | |
| Industry Key | |
| Ipo Expected Date | 2,025-05-01 |
| Language | en-US |
| Long Business Summary | Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPa blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis. The company was founded in 2018 is based in LA Palma, California. |
| Long Name | Liminatus Pharma, Inc. |
| Market | us_market |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_570895157 |
| Name Change Date | 2,026-04-19 |
| Net Income To Common | -10,206,517 |
| Open | 0.058 |
| Operating Cashflow | -9,963,318 |
| Operating Margins | 0.0 |
| Phone | 213 273 5453 |
| Prev Name | Liminatus Pharma, LLC |
| Previous Close | 0.0579 |
| Price Hint | 4 |
| Price To Book | -0.15950413 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.033 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0 |
| Regular Market Change Percent | 0.0 |
| Regular Market Day High | 0.0579 |
| Regular Market Day Low | 0.0579 |
| Regular Market Day Range | 0.0579 - 0.0579 |
| Regular Market Open | 0.058 |
| Regular Market Previous Close | 0.0579 |
| Regular Market Price | 0.0579 |
| Regular Market Time | 1,776,369,600 |
| Regular Market Volume | 1 |
| Return On Assets | -0.62646997 |
| Sand P52 Week Change | 0.38150132 |
| Sector | |
| Sector Key | |
| Short Name | Liminatus Pharma, Inc. Warrants |
| Source Interval | 15 |
| State | CA |
| Symbol | LIMNW |
| Total Cash | 337,655 |
| Total Cash Per Share | 0.008 |
| Total Debt | 1,442,500 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Type Disp | Equity |
| Volume | 1 |
| Website | https://liminatuspharma.com |
| Zip | 90,623 |